Medical Research Council leukaemia trial--UKALL V: an attempt to reduce the immunosuppressive effects of therapy in childhood acute lymphoblastic leukemia. Report to the Council by the Working Party on Leukaemia in Childhood.

Journal article

The Medical Research Council UKALL V trial for children with standard-risk acute lymphoblastic leukemia (ALL) (aged 1 to 14 years, leucocyte count less than 20 X 10(9)/L) was designed to determine whether the immunosuppressive effects of treatment could be reduced without sacrifice of antileukemic effect by alterations in the type of continuing therapy or in fractionation of cranial irradiation. Remission was achieved in 496 children on standard induction therapy, and 309 children received 24...

Expand abstract

Authors: Chessells, J; Durrant, J; Hardy, R; Richards, S

• Publication status: Published
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• Volume: 4
• Issue: 12
• Pages: 1758-1764
• Publication date: 1986-12-01
• EISSN: 1527-7755
• ISSN: 0732-183X
• Language: English
• Keywords: Leukemia, Lymphoid; Adolescent; Humans; 6-Mercaptopurine; England; Clinical Trials as Topic; Prednisone; Random Allocation; Child, Preschool; Antineoplastic Combined Chemotherapy Protocols; Methotrexate; Infant; Vincristine; Child